Category: Critical Evaluation of Cancer Research

Categories
Anti Cancer Cancer Research & Clinical Evidence Cancer Research Literacy Cancer Treatment Cancer Treatment Claims & Critical Analysis Cancer Treatment Options Cancer Treratments Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Fenbendazole Genetic Testing Gut-Microiome Integrative Oncology Insights Joe Tippins Non-Chemo Cancer Treatments Repurposed Drug Studies

Does Fenbendazole Really Treat Colorectal Cancer? What the 2026 Evidence Actually Shows Beyond the Joe Tippens Viral Story

fenbendazole and colorectal cancer have potential to change outcomes

This article from Courage Against Cancer evaluates the potential of fenbendazole, a veterinary drug, as a treatment for human colorectal cancer. Despite promising preclinical evidence, there are no conclusive human trials proving its efficacy. Patients are urged to discuss its use with oncologists, as risks such as liver toxicity exist.

Categories
Anti Cancer Cancer Research Literacy Cancer Support & Encouragement Cancer Treatment Cancer Treatment Guidance Cancer Treatment Options Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Health & Wellness Integrative Oncology Insights Ivermectin Joe Tippins Mebendazole Natural Treatments Non-Chemo Cancer Treatments Repurposed Drug Studies

The Joe Tippens Story: How a Veterinary Dewormer Became a Viral Cancer Cure Claim

Is ivermectin safe treatment for cancer

The article from Courage Against Cancer discusses Joe Tippens, whose recovery from small cell lung cancer was linked to fenbendazole, a veterinary dewormer. It emphasizes that his case lacks clinical validation and critical context, such as concurrent immunotherapy, highlighting the importance of distinguishing personal narratives from scientific evidence in cancer treatment discussions.

Categories
Anti Cancer Breakthrough Therapies Cancer Research & Clinical Evidence Cancer Support & Encouragement Cancer Treatment & Clinical Research Cancer Treatment Claims & Critical Analysis Cancer Treatment Research & Critical Analysis Cancer Wellness Protocols Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Gut Biome Gut-Microiome Health & Wellness Hulscher Study Integrative Oncology Insights Mebendazole Microbiome Non-Chemo Cancer Treatments Pancreatic Cancer Repurposed Drug Studies Research & Science Research News & Updates Wellness Company

What Is the Best Cancer Treatment for My Type and Stage of Cancer?

What Is the Best Cancer Treatment for My Type and Stage of Cancer

Courage Against Cancer emphasizes the importance of personalized cancer treatment plans, tailored based on cancer type, stage, and individual patient factors. This guide details various treatment modalities, including chemotherapy, radiation, immunotherapy, hormone therapy, and stem cell transplants, while encouraging patients to engage with their healthcare teams for informed decisions.

Categories
Anti Cancer Cancer Research & Clinical Evidence Cancer Support & Encouragement Cancer Treatment & Clinical Research Cancer Treatment Claims & Critical Analysis Cancer Treatment Research & Critical Analysis Clinical Trials & Cancer Treatment Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Health & Wellness Hulscher Study Ivermectin Joe Tippins Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Wellness Company

The Only Registered Human Ivermectin Oncology Trial (NCT05318469): What Is Actually Known

The Only Registered Human Ivermectin Oncology Trial

Courage Against Cancer emphasizes the importance of distinguishing between the registered trial NCT05318469 and the controversial Hulscher et al. 2026 study. The former aims to assess ivermectin’s safety and efficacy for metastatic triple-negative breast cancer under rigorous oversight, while the latter lacks validated endpoints and ethical scrutiny. Valid results are pending.

Categories
Anti Cancer Breakthrough Therapies Cancer Research & Clinical Evidence Cancer Research Literacy Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treratments Cancer Wellness Protocols Clinical Trials & Cancer Treatment Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Health & Wellness Hulscher Study Ivermectin Joe Tippins Mebendazole Non-Chemo Cancer Treatments Pancreatic Cancer Repurposed Drug Studies Research News & Updates Wellness Company

How Cancer Patients and Caregivers Should Evaluate Viral Claims About Unproven Treatments

Hulscher 2026 Study and how claims can go viral

The article from Courage Against Cancer emphasizes the importance of critically evaluating cancer treatment claims, particularly viral studies like the 2026 Hulscher et al. ivermectin-mebendazole paper. It provides a structured framework for assessing study validity, distinguishing between preclinical and clinical evidence, and understanding potential conflicts of interest to make informed treatment decisions.

Categories
Anti Cancer Breakthrough Therapies Cancer Research & Clinical Evidence Cancer Support & Encouragement Cancer Treatment & Outcomes Cancer Treatment Guidance Cancer Wellness Protocols Clinical Trials & Cancer Treatment Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Fenbendazole Gut-Microiome Health & Wellness Integrative Oncology Insights Ivermectin Joe Tippins Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Wellness Company

What Does an 84.4% ‘Clinical Benefit Rate’ Actually Mean — and What It Doesn’t

84 percent clinical benefit rate

Courage Against Cancer critiques the 2026 study by Hulscher et al., which claims an 84.4% clinical benefit rate from self-reported outcomes about off-label ivermectin and mebendazole in cancer patients. The study lacked control and independent verification, raising concerns over reliability and potential conflicts of interest. Caution is advised before drawing conclusions from such data.

Categories
Anti Cancer Breakthrough Therapies Cancer Treatment & Clinical Research Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treatment Options Cancer Wellness Protocols Clinical Trials & Cancer Treatment Critical Evaluation of Cancer Research drug repurposing Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Health & Wellness Hulscher Study Ivermectin Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Research & Science Research News & Updates Wellness Company

Is Ivermectin approved by the FDA as a cancer treatment for any type of cancer?

Is ivermectin FDA approved for cancer treatment

As of 2026, the FDA has not approved ivermectin for any cancer treatments; it is only sanctioned for specific parasitic infections. While off-label prescribing is legal, there is no solid evidence supporting its efficacy in oncology. Patients should consult their healthcare providers before altering treatment plans based on unverified claims.

Categories
Anti Cancer cancer research Cancer Support & Encouragement Cancer Treatment Cancer Treatment & Clinical Research Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treatment Guidance Cancer Wellness Protocols chemotherapy Clinical Trials & Cancer Treatment Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Health & Wellness Hulscher Study immunotherapy Ivermectin Mebendazole Non-Chemo Cancer Treatments Research & Science Research News & Updates

What questions should cancer patients ask their oncologist before considering off-label ivermectin based on this study?

The study by Hulscher et al. (2026) raised concerns regarding the use of ivermectin for cancer treatment, being observational and self-reported without rigorous trials. Potential conflicts of interest and unresolved questions about data integrity highlight the need for caution. Patients should discuss these issues with their oncologist and consider ongoing clinical trials.

Categories
Anti Cancer Breakthrough Therapies cancer research Cancer Treatment & Clinical Research Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treatment Guidance Critical Evaluation of Cancer Research Evaluating Cancer Treatment Claims Health & Wellness Hulscher Study immunotherapy Ivermectin Mebendazole preclinical trial Repurposed Drug Studies Research News & Updates

What were the main findings of the Hulscher et al. 2026 ivermectin cancer study published in Anticancer Research?

Written by Sean Kimbrough, Founder & Executive Director, Courage Against CancerSourced from peer-reviewed and IRB-registered clinical research · Last updated July 14, 2026

Categories
Anti Cancer cancer research Cancer Support & Encouragement Cancer Treatment Cancer Treatment & Clinical Research Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treatment Guidance Cluster Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Health & Wellness Hulscher Study Ivermectin Mebendazole

What is an ‘expression of concern’ from a scientific Hulscher 2026 ivermectin study financially connected to The Wellness Company?

An expression of concern (EOC) is a warning from a journal about potential issues in a study’s integrity without retracting it. Anticancer Research issued an EOC for Hulscher et al. (2026), citing data verifiability and ethical concerns, particularly due to conflicts of interest and reliance on self-reported outcomes without rigorous controls.